[Radiotherapy for prostate cancer].

A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med (2002) 10.64

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet (2002) 10.17

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol (2006) 5.20

Results of conservative management of clinically localized prostate cancer. N Engl J Med (1994) 5.04

Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA (1997) 3.80

Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol (2003) 3.73

Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol (2006) 3.12

The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol (2006) 2.71

PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer (2007) 2.27

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev (2006) 1.97

Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis. Cancer (2006) 1.82

Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys (2006) 1.60

Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modeling. Int J Radiat Oncol Biol Phys (2006) 1.50

Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not? Int J Radiat Oncol Biol Phys (2002) 1.45

The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review. Cancer (2007) 1.29

Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2007) 1.19

Intensity-modulated radiotherapy (IMRT) of localized prostate cancer: a review and future perspectives. Strahlenther Onkol (2007) 1.15

Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys (2006) 1.08

Emptying the rectum before treatment delivery limits the variations of rectal dose - volume parameters during 3DCRT of prostate cancer. Radiother Oncol (2006) 1.08

High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study. Int J Radiat Oncol Biol Phys (2006) 1.05

Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.01

Reduced late rectal mucosal changes after prostate three-dimensional conformal radiotherapy with endorectal balloon as observed in repeated endoscopy. Int J Radiat Oncol Biol Phys (2006) 0.99

High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. J Urol (2007) 0.99

Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma. BJU Int (2006) 0.95

Two different perspectives in the management of pT3 and/or margin-positive prostate cancer after radical prostatectomy. BJU Int (2006) 0.94

Postoperative radiotherapy for prostate cancer : evaluation of target motion and treatment techniques (intensity-modulated versus conformal radiotherapy). Strahlenther Onkol (2007) 0.87

Long-term benefits of elective radiotherapy after prostatectomy for patients with positive surgical margins. J Urol (2006) 0.85

Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1-T2 prostate cancer. Radiother Oncol (2006) 0.85

A systematic review of randomized trials in localized prostate cancer. Can J Urol (2004) 0.84

Transperineal permanent seed implantation of "low-risk" prostate cancer: 5-year-experiences in 118 patients. Strahlenther Onkol (2006) 0.82

High dose rate iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer. Clin Oncol (R Coll Radiol) (2006) 0.81

Clinical and biochemical outcome of conventional dose radiotherapy for localized prostate cancer. Can J Urol (2002) 0.79

Toward the optimal use of androgen suppression therapy in the radiotherapeutic management of prostate cancer. J Clin Oncol (2007) 0.78

Acute and late genitourinary toxicity of conformal radiotherapy for prostate cancer. Radiat Med (2006) 0.78

State-of-the-art radiotherapy in the management of clinically localized prostate carcinoma. Future Oncol (2007) 0.77

Quality assurance of the 22961 EORTC trial. A phase III study of the optimal combination of hormonal adjuvant treatment by LHRH analogue and radiation therapy for the management of locally advanced prostate cancer: the dummy run. Radiother Oncol (2004) 0.76